| abstract |
The present invention relates to the use of a compound that induces proinsulin activity, preferably human proinsulin, for the preparation of a medicament or pharmaceutical composition for the prevention and treatment of neurodegenerative conditions, disorders or diseases in which cell death occurs. programmed, preferably neurodegenerative pathologies of the central and peripheral nervous system, and more preferably of the group of inherited degenerative diseases known as pigmentary retinosis. The activator compound may consist of a chemical molecule, a peptide, a protein or a nucleotide sequence. |